<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02478502</url>
  </required_header>
  <id_info>
    <org_study_id>2012/1627 b</org_study_id>
    <secondary_id>2012-004418-32</secondary_id>
    <nct_id>NCT02478502</nct_id>
  </id_info>
  <brief_title>Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer</brief_title>
  <official_title>Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jan Oldenburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Germ cell tumors belong to the most chemosensitive malignancies. Paclitaxel in combination
      with ifosfamide and cisplatin (TIP) has become a common regimen for salvage treatment of germ
      cell cancer.

      Cabazitaxel may overcome resistance to docetaxel and paclitaxel and might have clinical
      activity in patients with metastatic and progressive germ cell tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with metastatic germ cell cancer and relapse after two or more courses of
      cisplatin-based chemotherapy or after high-dose chemotherapy have a poor prognosis and no
      curative options. Taxanes in various combinations unfold cytotoxic effects on germ cell
      tumors resistant to conventional doses of cisplatin. Paclitaxel in combination with
      ifosfamide and cisplatin (TIP) has become a common regimen for salvage treatment of germ cell
      cancer. In most patients, however, resistance to paclitaxel, as evidenced by progression
      occurs.Cabazitaxel has been developed to overcome resistance to docetaxel and paclitaxel. It
      has shown efficacy in patients progressing during docetaxel therapy in a large phase III
      trial (TROPIC) in patients with castration-resistant prostate cancer. Furthermore,
      chemotherapy resistance might be less likely to develop in patients receiving cabazitaxel as
      compared to other taxanes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>after 3 and 6 cycles of cabazitaxel (9 and 18 weeks, respectively) as change from baseline (radiologic evaluation before first cycle of cabazitaxel)</time_frame>
    <description>Recist 1.1</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Testicular Cancer</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel (single arm study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabazitaxel 25 mg/m2 each 3. week (no other drugs will be administered)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabazitaxel</intervention_name>
    <description>cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy</description>
    <arm_group_label>Cabazitaxel (single arm study)</arm_group_label>
    <other_name>Jevtana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients ≥ 18 years old

          -  Histologically verified metastatic germ cell cancer (GCC) of the testicle or
             extragonadal GCC originating from retroperitoneum or mediastinum

          -  Disease progression during cisplatin-based chemotherapy or Disease progression or
             relapse after high-dose chemotherapy or Disease progression or relapse after at least
             2 different cisplatin-based regimens

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-2

          -  Life expectancy ≥ 3 months

          -  At baseline adequate function of liver, kidneys and bone marrow:

        ·Neutrophils ≥ 1.5 x 109/L·

          -  Hemoglobin ≥ 9.0 g/dL

          -  Platelets ≥ 100 x 109/L

          -  Creatinine ≤ 1.5 x upper limit of normal (ULN)

          -  Total Bilirubin ≤ 1.0 x ULN

          -  Serum glutamate oxaloacetate transaminase (SGOT/AST) ≤ 1.5 x ULN

          -  Serum glutamate pyruvate transaminase (SGPT/ALT) &lt; 1.5 x ULN

        Exclusion Criteria:

          -  Systemic antitumor treatment within 21 days before study entry

          -  Simultaneous radiotherapy to the only target lesion

          -  Patients unwilling or unable to comply with the protocol

          -  Patients with unstable angina pectoris, myocardial infarction ≤ 6 months prior to
             first study treatment, congestive heart failure New York Heart Association (NYHA)
             III-IV or serious uncontrolled cardiac arrhythmias

          -  Patients with an active or uncontrolled infection

          -  Patients who have a history of another primary malignancy and are off treatment for ≤
             3 years, with the exception of non-melanoma skin cancer

          -  Patients who have undergone major surgery within 4 weeks prior to starting study drug
             (e.g. intra-thoracic, intra-abdominal, or intra-pelvic) or significant traumatic
             injury, or who have not recovered from the side effects of any of the above within 6
             weeks

          -  Patients who have participated in another interventional clinical trial within 30 days
             before study entry

          -  Other serious medical conditions that could impair the ability of the patient to
             participate in the study

          -  Active infection requiring systemic antibiotic-, anti-viral-, or anti-fungal
             medication

          -  Neuropathy ≥Grade 2 Common Terminology Criteria for Adverse Events (CTCAE)

          -  Patient with reproductive potential not implementing accepted and effective method of
             contraception during the whole study period and up to 6 months after the last dose of
             cabazitaxel

          -  One or more of the following cabazitaxel-specific requirements:

               -  History of severe hypersensitivity reaction (≥ Grade 3) to docetaxel

               -  History of severe hypersensitivity reaction (≥ Grade 3) to polysorbate 80
                  containing drugs

               -  Concurrent or planned treatment with strong inhibitors or strong inducers of
                  cytochrome P450 3A4 (CYP3A4) (a one week wash-out period is necessary for
                  patients who are already on these treatments) (see Appendix A and B)

               -  Concurrent or planned treatment with Organic anion transporting polypeptide1B1
                  (OATP1B1) substrates e.g. statins, valsartan, repaglinide which have to be taken
                  within 12 hours before cabazitaxel application and 3 hours after the end of
                  infusion, refer table 9
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Oldenburg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Oldenburg, MD, PhD</last_name>
    <phone>91502900</phone>
    <phone_ext>+47</phone_ext>
    <email>jan.oldenburg@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisbeth Johnsen, M.Sc</last_name>
    <phone>45246719</phone>
    <phone_ext>+47</phone_ext>
    <email>lisbeth.johnsen@ahus.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gedske Daugaard, MD, PhD</last_name>
      <phone>35453545</phone>
      <phone_ext>+45</phone_ext>
      <email>gedske.daugaard@rh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Gedske Daugaard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carsten Bokemeyer, MD, PhD</last_name>
      <phone>40 741053962</phone>
      <phone_ext>+49</phone_ext>
      <email>c.bokemeyer@uke.uni-hamburg.de</email>
    </contact>
    <investigator>
      <last_name>Carsten Bokemeyer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T)</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene Negaard, MD, PhD</last_name>
      <phone_ext>+47</phone_ext>
      <email>UXHEGA@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Marit Husby, MD</last_name>
      <phone>23026600</phone>
      <phone_ext>+47</phone_ext>
      <email>UXHUMC@ous-hf.no</email>
    </contact_backup>
    <investigator>
      <last_name>Helene Negaard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Uppsala, Department of Oncology</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2014</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2015</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Jan Oldenburg</investigator_full_name>
    <investigator_title>MD, PhD, Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>testicular cancer</keyword>
  <keyword>cisplatin resistancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

